Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans.

Conway OJ, Carrasquillo MM, Wang X, Bredenberg JM, Reddy JS, Strickland SL, Younkin CS, Burgess JD, Allen M, Lincoln SJ, Nguyen T, Malphrus KG, Soto AI, Walton RL, Boeve BF, Petersen RC, Lucas JA, Ferman TJ, Cheshire WP, van Gerpen JA, Uitti RJ, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Ertekin-Taner N.

Mol Neurodegener. 2018 Oct 11;13(1):53. doi: 10.1186/s13024-018-0289-x.

2.

Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy.

Allen M, Wang X, Serie DJ, Strickland SL, Burgess JD, Koga S, Younkin CS, Nguyen TT, Malphrus KG, Lincoln SJ, Alamprese M, Zhu K, Chang R, Carrasquillo MM, Kouri N, Murray ME, Reddy JS, Funk C, Price ND, Golde TE, Younkin SG, Asmann YW, Crook JE, Dickson DW, Ertekin-Taner N.

Acta Neuropathol. 2018 Nov;136(5):709-727. doi: 10.1007/s00401-018-1900-5. Epub 2018 Aug 22.

3.

An alternative transcript of the Alzheimer's disease risk gene SORL1 encodes a truncated receptor.

Blechingberg J, Poulsen ASA, Kjølby M, Monti G, Allen M, Ivarsen AK, Lincoln SJ, Thotakura G, Vægter CB, Ertekin-Taner N, Nykjær A, Andersen OM.

Neurobiol Aging. 2018 Nov;71:266.e11-266.e24. doi: 10.1016/j.neurobiolaging.2018.06.021. Epub 2018 Jun 28.

PMID:
30078640
4.

ABCA7 loss-of-function variants, expression, and neurologic disease risk.

Allen M, Lincoln SJ, Corda M, Watzlawik JO, Carrasquillo MM, Reddy JS, Burgess JD, Nguyen T, Malphrus K, Petersen RC, Graff-Radford NR, Dickson DW, Ertekin-Taner N.

Neurol Genet. 2017 Jan 5;3(1):e126. doi: 10.1212/NXG.0000000000000126. eCollection 2017 Feb.

5.

Evaluating pathogenic dementia variants in posterior cortical atrophy.

Carrasquillo MM, Barber I, Lincoln SJ, Murray ME, Camsari GB, Khan QUA, Nguyen T, Ma L, Bisceglio GD, Crook JE, Younkin SG, Dickson DW, Boeve BF, Graff-Radford NR, Morgan K, Ertekin-Taner N.

Neurobiol Aging. 2016 Jan;37:38-44. doi: 10.1016/j.neurobiolaging.2015.09.023. Epub 2015 Oct 8.

6.

Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, Schroeder AS, Zhang L, Bowles E, Behrouz B, Lincoln SJ, Beevers JE, Milnerwood AJ, Kurti A, McLean PJ, Fryer JD, Springer W, Dickson DW, Farrer MJ, Melrose HL.

Neurobiol Dis. 2015 Jun;78:172-95. doi: 10.1016/j.nbd.2015.02.031. Epub 2015 Mar 31.

7.

LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors.

Hinkle KM, Yue M, Behrouz B, Dächsel JC, Lincoln SJ, Bowles EE, Beevers JE, Dugger B, Winner B, Prots I, Kent CB, Nishioka K, Lin WL, Dickson DW, Janus CJ, Farrer MJ, Melrose HL.

Mol Neurodegener. 2012 May 30;7:25. doi: 10.1186/1750-1326-7-25.

8.

First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation.

Puschmann A, Englund E, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, Cobb SA, Törnqvist AL, Rehncrona S, Widner H, Wszolek ZK, Farrer MJ, Nilsson C.

Parkinsonism Relat Disord. 2012 May;18(4):332-8. doi: 10.1016/j.parkreldis.2011.11.019. Epub 2011 Dec 6.

9.

Translation initiator EIF4G1 mutations in familial Parkinson disease.

Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, Lincoln SJ, Leprêtre F, Hulihan MM, Kachergus J, Milnerwood AJ, Tapia L, Song MS, Le Rhun E, Mutez E, Larvor L, Duflot A, Vanbesien-Mailliot C, Kreisler A, Ross OA, Nishioka K, Soto-Ortolaza AI, Cobb SA, Melrose HL, Behrouz B, Keeling BH, Bacon JA, Hentati E, Williams L, Yanagiya A, Sonenberg N, Lockhart PJ, Zubair AC, Uitti RJ, Aasly JO, Krygowska-Wajs A, Opala G, Wszolek ZK, Frigerio R, Maraganore DM, Gosal D, Lynch T, Hutchinson M, Bentivoglio AR, Valente EM, Nichols WC, Pankratz N, Foroud T, Gibson RA, Hentati F, Dickson DW, Destée A, Farrer MJ.

Am J Hum Genet. 2011 Sep 9;89(3):398-406. doi: 10.1016/j.ajhg.2011.08.009.

10.

VPS35 mutations in Parkinson disease.

Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL, Hentati E, Puschmann A, Evans DM, Conibear E, Wasserman WW, Aasly JO, Burkhard PR, Djaldetti R, Ghika J, Hentati F, Krygowska-Wajs A, Lynch T, Melamed E, Rajput A, Rajput AH, Solida A, Wu RM, Uitti RJ, Wszolek ZK, Vingerhoets F, Farrer MJ.

Am J Hum Genet. 2011 Jul 15;89(1):162-7. doi: 10.1016/j.ajhg.2011.06.001. Erratum in: Am J Hum Genet. 2011 Aug 12;89(2):347.

11.

Common variants in PARK loci and related genes and Parkinson's disease.

Chung SJ, Armasu SM, Biernacka JM, Lesnick TG, Rider DN, Lincoln SJ, Ortolaza AI, Farrer MJ, Cunningham JM, Rocca WA, Maraganore DM.

Mov Disord. 2011 Feb 1;26(2):280-8. doi: 10.1002/mds.23376. Epub 2010 Dec 13.

12.

Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease.

Nishioka K, Wider C, Vilariño-Güell C, Soto-Ortolaza AI, Lincoln SJ, Kachergus JM, Jasinska-Myga B, Ross OA, Rajput A, Robinson CA, Ferman TJ, Wszolek ZK, Dickson DW, Farrer MJ.

Arch Neurol. 2010 Aug;67(8):970-5. doi: 10.1001/archneurol.2010.177.

13.

Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.

Aasly JO, Vilariño-Güell C, Dachsel JC, Webber PJ, West AB, Haugarvoll K, Johansen KK, Toft M, Nutt JG, Payami H, Kachergus JM, Lincoln SJ, Felic A, Wider C, Soto-Ortolaza AI, Cobb SA, White LR, Ross OA, Farrer MJ.

Mov Disord. 2010 Oct 15;25(13):2156-63. doi: 10.1002/mds.23265.

14.

Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

Melrose HL, Dächsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, Kent CB, Korvatska E, Taylor JP, Witten L, Liang YQ, Beevers JE, Boules M, Dugger BN, Serna VA, Gaukhman A, Yu X, Castanedes-Casey M, Braithwaite AT, Ogholikhan S, Yu N, Bass D, Tyndall G, Schellenberg GD, Dickson DW, Janus C, Farrer MJ.

Neurobiol Dis. 2010 Dec;40(3):503-17. doi: 10.1016/j.nbd.2010.07.010. Epub 2010 Jul 24.

15.

Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease.

Dachsel JC, Nishioka K, Vilariño-Güell C, Lincoln SJ, Soto-Ortolaza AI, Kachergus J, Hinkle KM, Heckman MG, Jasinska-Myga B, Taylor JP, Dickson DW, Gibson RA, Hentati F, Ross OA, Farrer MJ.

Mech Ageing Dev. 2010 Mar;131(3):210-4. doi: 10.1016/j.mad.2010.01.009. Epub 2010 Feb 6.

16.

Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population.

Rajput A, Vilariño-Güell C, Rajput ML, Ross OA, Soto-Ortolaza AI, Lincoln SJ, Cobb SA, Heckman MG, Farrer MJ, Rajput A.

Mov Disord. 2009 Dec 15;24(16):2411-4. doi: 10.1002/mds.22795.

PMID:
19890971
17.

A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction.

Puschmann A, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, Cobb SA, Lindquist SG, Nielsen JE, Wszolek ZK, Farrer M, Widner H, van Westen D, Hägerström D, Markopoulou K, Chase BA, Nilsson K, Reimer J, Nilsson C.

Parkinsonism Relat Disord. 2009 Nov;15(9):627-32. doi: 10.1016/j.parkreldis.2009.06.007. Epub 2009 Jul 25.

18.

Dopamine transporter genetic variants and pesticides in Parkinson's disease.

Ritz BR, Manthripragada AD, Costello S, Lincoln SJ, Farrer MJ, Cockburn M, Bronstein J.

Environ Health Perspect. 2009 Jun;117(6):964-9. doi: 10.1289/ehp.0800277. Epub 2009 Feb 22.

19.

Phactr2 and Parkinson's disease.

Wider C, Lincoln SJ, Heckman MG, Diehl NN, Stone JT, Haugarvoll K, Aasly JO, Gibson JM, Lynch T, Rajput A, Rajput ML, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA.

Neurosci Lett. 2009 Mar 27;453(1):9-11. doi: 10.1016/j.neulet.2009.02.009. Epub 2009 Feb 10.

20.

ATP13A2 variability in Parkinson disease.

Vilariño-Güell C, Soto AI, Lincoln SJ, Ben Yahmed S, Kefi M, Heckman MG, Hulihan MM, Chai H, Diehl NN, Amouri R, Rajput A, Mash DC, Dickson DW, Middleton LT, Gibson RA, Hentati F, Farrer MJ.

Hum Mutat. 2009 Mar;30(3):406-10. doi: 10.1002/humu.20877.

21.

Genotype-phenotype correlates in Taiwanese patients with early-onset recessive Parkinsonism.

Lee MJ, Mata IF, Lin CH, Tzen KY, Lincoln SJ, Bounds R, Lockhart PJ, Hulihan MM, Farrer MJ, Wu RM.

Mov Disord. 2009 Jan 15;24(1):104-8. doi: 10.1002/mds.22093.

PMID:
19006224
22.

Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia.

Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ, Finch N, Rutherford NJ, Crook RJ, Josephs KA, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Caselli RJ, Wszolek ZK, Uitti RJ, Feldman H, Hutton ML, Mackenzie IR, Graff-Radford NR, Dickson DW.

Hum Mol Genet. 2008 Dec 1;17(23):3631-42. doi: 10.1093/hmg/ddn257. Epub 2008 Aug 21.

23.

Alpha-synuclein, pesticides, and Parkinson disease: a case-control study.

Brighina L, Frigerio R, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, Farrer MJ, Lincoln SJ, Checkoway H, Rocca WA, Maraganore DM.

Neurology. 2008 Apr 15;70(16 Pt 2):1461-9. doi: 10.1212/01.wnl.0000304049.31377.f2. Epub 2008 Mar 5.

PMID:
18322262
24.

A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease.

Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, Lincoln SJ, Mok SS, Culvenor JG, Masters CL, Tyndall GM, Bass DI, Ahmed Z, Andorfer CA, Ross OA, Wszolek ZK, Delldonne A, Dickson DW, Farrer MJ.

Neuroscience. 2007 Jul 29;147(4):1047-58. Epub 2007 Jul 3.

PMID:
17611037
25.

Beta-synuclein gene variants and Parkinson's disease: a preliminary case-control study.

Brighina L, Okubadejo NU, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, Farrer MJ, Lincoln SJ, Rocca WA, Maraganore DM.

Neurosci Lett. 2007 Jun 15;420(3):229-34. Epub 2007 May 21.

26.

Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease.

Ross OA, Gosal D, Stone JT, Lincoln SJ, Heckman MG, Irvine GB, Johnston JA, Gibson JM, Farrer MJ, Lynch T.

Mech Ageing Dev. 2007 May-Jun;128(5-6):378-82. Epub 2007 Apr 24.

27.

Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy.

Lincoln SJ, Ross OA, Milkovic NM, Dickson DW, Rajput A, Robinson CA, Papapetropoulos S, Mash DC, Farrer MJ.

Parkinsonism Relat Disord. 2007 Aug;13(6):340-2. Epub 2007 Feb 8.

28.

Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease.

Taylor JP, Hulihan MM, Kachergus JM, Melrose HL, Lincoln SJ, Hinkle KM, Stone JT, Ross OA, Hauser R, Aasly J, Gasser T, Payami H, Wszolek ZK, Farrer MJ.

Neurogenetics. 2007 Apr;8(2):95-102. Epub 2007 Jan 16.

PMID:
17225181
29.

Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2.

Dächsel JC, Mata IF, Ross OA, Taylor JP, Lincoln SJ, Hinkle KM, Huerta C, Ribacoba R, Blazquez M, Alvarez V, Farrer MJ.

Neurosci Lett. 2006 Dec 20;410(2):80-4.

PMID:
17095157
30.

The ups and downs of alpha-synuclein mRNA expression.

Dächsel JC, Lincoln SJ, Gonzalez J, Ross OA, Dickson DW, Farrer MJ.

Mov Disord. 2007 Jan 15;22(2):293-5. Review. No abstract available.

PMID:
17094104
31.

Parkinsonism, Lrrk2 G2019S, and tau neuropathology.

Rajput A, Dickson DW, Robinson CA, Ross OA, Dächsel JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ.

Neurology. 2006 Oct 24;67(8):1506-8.

PMID:
17060589
32.

Internal capsule size in good-outcome and poor-outcome schizophrenia.

Brickman AM, Buchsbaum MS, Ivanov Z, Borod JC, Foldi NS, Hahn E, Mitelman SA, Hazlett EA, Lincoln SJ, Newmark RE, Shihabuddin L.

J Neuropsychiatry Clin Neurosci. 2006 Summer;18(3):364-76.

PMID:
16963586
33.

Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.

Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, Hulihan MM, Aasly JO, Ashizawa T, Chartier-Harlin MC, Checkoway H, Ferrarese C, Hadjigeorgiou G, Hattori N, Kawakami H, Lambert JC, Lynch T, Mellick GD, Papapetropoulos S, Parsian A, Quattrone A, Riess O, Tan EK, Van Broeckhoven C; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.

JAMA. 2006 Aug 9;296(6):661-70.

PMID:
16896109
34.

Genomewide association, Parkinson disease, and PARK10.

Farrer MJ, Haugarvoll K, Ross OA, Stone JT, Milkovic NM, Cobb SA, Whittle AJ, Lincoln SJ, Hulihan MM, Heckman MG, White LR, Aasly JO, Gibson JM, Gosal D, Lynch T, Wszolek ZK, Uitti RJ, Toft M.

Am J Hum Genet. 2006 Jun;78(6):1084-8; author reply 1092-4. No abstract available.

35.

Parkinson's disease: a rethink of rodent models.

Melrose HL, Lincoln SJ, Tyndall GM, Farrer MJ.

Exp Brain Res. 2006 Aug;173(2):196-204. Epub 2006 Apr 26. Review.

PMID:
16639500
36.

Lrrk2 R1441 substitution and progressive supranuclear palsy.

Ross OA, Whittle AJ, Cobb SA, Hulihan MM, Lincoln SJ, Toft M, Farrer MJ, Dickson DW.

Neuropathol Appl Neurobiol. 2006 Feb;32(1):23-5.

PMID:
16409550
37.

Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD.

Gosal D, Ross OA, Wiley J, Irvine GB, Johnston JA, Toft M, Mata IF, Kachergus J, Hulihan M, Taylor JP, Lincoln SJ, Farrer MJ, Lynch T, Mark Gibson J.

Parkinsonism Relat Disord. 2005 Sep;11(6):349-52.

PMID:
16102999
38.

Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism.

Mata IF, Alvarez V, Coto E, Blazquez M, Guisasola LM, Salvador C, Kachergus JM, Lincoln SJ, Farrer M.

Neurosci Lett. 2005 Jun 3;380(3):257-9. Epub 2005 Feb 8.

PMID:
15862897
39.

Interaction of alpha-synuclein and tau genotypes in Parkinson's disease.

Mamah CE, Lesnick TG, Lincoln SJ, Strain KJ, de Andrade M, Bower JH, Ahlskog JE, Rocca WA, Farrer MJ, Maraganore DM.

Ann Neurol. 2005 Mar;57(3):439-43.

PMID:
15732111
40.

Parkin variants in North American Parkinson's disease: cases and controls.

Lincoln SJ, Maraganore DM, Lesnick TG, Bounds R, de Andrade M, Bower JH, Hardy JA, Farrer MJ.

Mov Disord. 2003 Nov;18(11):1306-11.

PMID:
14639672
41.

Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease.

Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA.

Neurology. 1999 Nov 10;53(8):1858-60.

PMID:
10563640

Supplemental Content

Loading ...
Support Center